To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given ov
Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors
β Scribed by Ruprecht Nitschke; Charles Pratt; Michael Harris; Jeffrey Krischer; Teresa J. Vietti; Holcombe Grier; Willem Kamps; Stuart Toledano
- Publisher
- Springer US
- Year
- 1992
- Tongue
- English
- Weight
- 293 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by inves
## Abstract The __hSNF5/INI1__ gene, which encodes a subunit of the SWI/SNF family of chromatinβremodeling complexes and is located at 22q11.2, has been reported as a tumor suppressor gene inactivated in malignant rhabdoid tumors (MRTs). We analyzed this gene in varieties of pediatric solid tumors
## Abstract ## BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patie